FFG Austrian Life Sciences

FFG Austrian Life Sciences sits under the Austrian Research Promotion Agency (FFG) and backs Austria's life sciences sector through company-led R&D projects and clinical studies. The initiative covers digitalization with health aspects, new drugs, medical devices, and interventional phase I and II studies, making it one of the more clinically oriented routes in FFG's programme set. The funding caps in the record are EUR 3 million for experimental development and clinical studies and EUR 1 million for industrial research. The initiative runs through eCall until 18 December 2026, with seven decision-board meetings per year, and the total programme budget is EUR 45 million for 2024-2026. Participation across the value chain is required, foreign partners may participate depending on the instrument, and the 2026 cohort is company-only. The programme suits companies that can lead a life sciences project from development into evidence generation and that can work within TRL 2-8 depending on the activity. It is especially notable because clinical studies are funded at TRL 2-4, which is unusual for FFG. Applicants should read the current call as a company-led route, since the broader project path that would open eligibility to universities and research institutions is not offered in 2026.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.